EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
Frontiers in Pharmacology · 02.08.2023 · 14
DOI: 10.3389/fphar.2023.1238639 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.08.2023. Verfasst von Hee-Jeong Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neural Development and Disease, Korea Brain Research Institute (KBRI), Daegu, Republic of Korea. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Many researchers are attempting to identify drugs that can be repurposed as effective therapies for Alzheimer’s disease (AD). Several recent studies have highlighted epidermal growth factor receptor (EGFR) inhibitors approved for use as anti-cancer drugs as potential candidates for repurposing as AD therapeutics. In cancer, EGFR inhibitors target cell proliferation and angiogenesis, and studies in AD mouse models have shown that EGFR inhibitors can attenuate amyloid-beta (Aβ) pathology and improve cognitive function. In this review, we discuss the different functions of EGFR in cancer and AD and the potential of EGFR as a dual molecular target for AD diseases. In addition, we describe the effects of anti-cancer EGFR tyrosine kinase inhibitors (TKIs) on AD pathology and their prospects as therapeutic interventions for AD. By summarizing the physiological functions of EGFR in cancer and AD, this review emphasizes the significance of EGFR as an important molecular target for these diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neural Development and Disease, Korea Brain Research Institute (KBRI), Daegu, Republic of Korea.
- Department of Brain and Cognitive Sciences, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Republic of Korea.
- Department of Bio-Health Technology, College of Biomedical Science, Kangwon National University, Chuncheon, Republic of Korea.
Zitieren
APA
Choi, H. J., Jeong, Y. J., Kim, J., & Hoe, H. S. (2023). EGFR is a potential dual molecular target for cancer and Alzheimer’s disease. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1238639
Vancouver
Choi HJ, Jeong YJ, Kim J, Hoe HS. EGFR is a potential dual molecular target for cancer and Alzheimer’s disease. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1238639
BibTeX
@article{Choi2023,
author = {Choi, Hee-Jeong and Jeong, Yoo Joo and Kim, Jieun and Hoe, Hyang-Sook},
title = {EGFR is a potential dual molecular target for cancer and Alzheimer’s disease},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1238639}
}
EUVIMED